{"title":"The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses.","authors":"Huiqiao Gu, Xu Xie, Qiuying Lv, Yuantian Cui, Ziyan Lu, Zaure Akhmetova, Zarina Shulgau, Fang Huang, Yawen Jiang","doi":"10.1007/s40121-026-01331-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Varicella, caused by the varicella zoster virus, poses a significant public health challenge, particularly among children. To address this, the city of Shenzhen, China, introduced a publicly funded vaccination program offering free two-dose varicella vaccines to eligible school-aged cohorts. This study aims to evaluate the program's impact on disease incidence, vaccination uptake, and the comparative effectiveness of two-dose versus single-dose regimens.</p><p><strong>Methods: </strong>We used the individual-level data from official immunization and surveillance systems, covering pupils born between 1 September 2014 and 31 August 2015. Applying a difference-in-differences approach, we compared the disease incidence and vaccination uptake between the eligible cohort and ineligible cohort. Additionally, to further evaluate the effectiveness of the two-dose vaccination schedule, we implemented a regression discontinuity design using the policy cutoff date.</p><p><strong>Result: </strong>The policy reduced varicella incidence by 22.96% (95% CI 8.98-34.79%, p < 0.05) in the eligible cohort relative to the ineligible one, while boosting first- and second-dose coverage by 34.97% (95% CI 28.19-2.11%, p < 0.05) and 98.05% (95% CI 91.98-104.31%, p < 0.05), respectively. The regression discontinuity design indicated that the two-dose schedule conferred 75.19% (95% CI 70.62-79.06%) relative vaccine effectiveness against breakthrough varicella after a single dose. This study's main limitation is that, while reporting of varicella cases is mandatory, underreporting and misdiagnosis remain possible, potentially underestimating true incidence.</p><p><strong>Conclusions: </strong>These findings demonstrate the program's success in reducing disease burden and enhancing immunization rates, underscoring the superior protection of two-dose vaccination and providing strong evidence for policymakers to expand such initiatives.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"1369-1384"},"PeriodicalIF":5.3000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129005/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-026-01331-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Varicella, caused by the varicella zoster virus, poses a significant public health challenge, particularly among children. To address this, the city of Shenzhen, China, introduced a publicly funded vaccination program offering free two-dose varicella vaccines to eligible school-aged cohorts. This study aims to evaluate the program's impact on disease incidence, vaccination uptake, and the comparative effectiveness of two-dose versus single-dose regimens.
Methods: We used the individual-level data from official immunization and surveillance systems, covering pupils born between 1 September 2014 and 31 August 2015. Applying a difference-in-differences approach, we compared the disease incidence and vaccination uptake between the eligible cohort and ineligible cohort. Additionally, to further evaluate the effectiveness of the two-dose vaccination schedule, we implemented a regression discontinuity design using the policy cutoff date.
Result: The policy reduced varicella incidence by 22.96% (95% CI 8.98-34.79%, p < 0.05) in the eligible cohort relative to the ineligible one, while boosting first- and second-dose coverage by 34.97% (95% CI 28.19-2.11%, p < 0.05) and 98.05% (95% CI 91.98-104.31%, p < 0.05), respectively. The regression discontinuity design indicated that the two-dose schedule conferred 75.19% (95% CI 70.62-79.06%) relative vaccine effectiveness against breakthrough varicella after a single dose. This study's main limitation is that, while reporting of varicella cases is mandatory, underreporting and misdiagnosis remain possible, potentially underestimating true incidence.
Conclusions: These findings demonstrate the program's success in reducing disease burden and enhancing immunization rates, underscoring the superior protection of two-dose vaccination and providing strong evidence for policymakers to expand such initiatives.
由水痘带状疱疹病毒引起的水痘是一项重大的公共卫生挑战,特别是在儿童中。为了解决这个问题,中国深圳市推出了一项公共资助的疫苗接种计划,向符合条件的学龄人群免费提供两剂水痘疫苗。本研究旨在评估该计划对疾病发病率、疫苗接种率的影响,以及两剂与单剂方案的比较有效性。方法:我们使用来自官方免疫和监测系统的个人数据,涵盖2014年9月1日至2015年8月31日出生的小学生。采用差异中的差异方法,我们比较了符合条件的队列和不符合条件的队列之间的疾病发病率和疫苗接种率。此外,为了进一步评估两剂疫苗接种计划的有效性,我们使用政策截止日期实施了回归不连续设计。结果:该政策将水痘发病率降低了22.96% (95% CI 8.98-34.79%)。结论:这些发现表明该计划在减轻疾病负担和提高免疫率方面取得了成功,强调了两剂疫苗接种的优越保护作用,并为政策制定者扩大此类举措提供了有力证据。
期刊介绍:
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.